Efeito dos Campos de Tratamento Tumoral Mais Temozolomida de Manutenção vs Temozolomida de Manutenção Sozinha na Sobrevivência de Pacientes com Glioblastoma

Stupp et al. (Terça,) estudaram esta questão.

www.synapsesocial.com/papers/69d8a923ce048d2571bed979 — DOI: https://doi.org/10.1001/jama.2017.18718

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma· 2015 · 1,216 citations
2. Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression· 2010 · 22 citations
3. Interim analysis: The alpha spending function approach· 1994 · 568 citations
4. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial· 2014 · 1,015 citations
5. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial· 2012 · 83 citations